Proteins that inhibit hyperinflammatory responses and uses thereof

By binding soluble CD4 recombinant protein to macrophage MHC II and inhibiting TLR4-mediated inflammatory response, the problem of the inability to effectively control the excessive inflammatory response in sepsis in existing technologies has been solved, thus achieving effective treatment of sepsis.

CN118662607BActive Publication Date: 2026-07-07SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Filing Date
2023-03-15
Publication Date
2026-07-07

Smart Images

  • Figure HDA0004127358990000011
    Figure HDA0004127358990000011
  • Figure HDA0004127358990000012
    Figure HDA0004127358990000012
  • Figure HDA0004127358990000013
    Figure HDA0004127358990000013
Patent Text Reader

Abstract

Disclosed are proteins and uses thereof for inhibiting hyperinflammatory responses. The proteins include soluble CD4 molecules (sCD4), and the uses include preventing or treating sepsis hyperinflammatory responses or macrophage hyperinflammatory responses. Also disclosed is that the target of sCD4 for inhibiting macrophage hyperinflammatory responses is cell membrane type MHC II, and the sCD4 exerts its effects by regulating the MHC II / STING / SHP2 complex.
Need to check novelty before this filing date? Find Prior Art